Home > Organization > Fundamental Innovative Oncology Core > Biomarker and Therapeutic Target Research Core > Department of Biomarkers for Early Detection of Cancer > Research Projects > Practical implementation of effective blood biomarker-based pancreatic cancer screening
Practical implementation of effective blood biomarker-based pancreatic cancer screening
The biomarker is an isoform of apolipoprotein (apo) A2, a protein that circulates in the blood, and the NCC Research Institute has been collaborating with the National Cancer Institute (NCI) in the United States to assess biomarker effectiveness for detecting early-stage pancreatic cancer and precancerous conditions associated with a high risk of pancreatic malignancy, and to develop a test kit. Based on the results of this study, trial screenings for pancreatic cancer were carried out in a collaborative study with Kobe University and others starting in 2015. In those trial screenings, abnormal biomarker values enabled detection of pancreatic cancer and precancerous conditions associated with a risk of pancreatic malignancy. A follow-up study using community-wide health examinations in Kagoshima Prefecture, Japan, began in July 2017.